SS-31 is a research name associated with elamipretide. Forzinity is a specific finished medicine containing elamipretide. Recognizing that relationship is useful, but treating the three names as interchangeable product guarantees is a mistake.
An ingredient name is not an approval
The FDA granted Forzinity accelerated approval in September 2025 for improving muscle strength in people with Barth syndrome who meet the labeled weight requirement. That decision does not approve every item advertised as SS-31, every formulation of elamipretide, or use for general energy and longevity. FDA approval announcement.
There are several separate questions: what substance is claimed, what the container actually contains, how the finished product was manufactured, and which clinical use has been evaluated. A familiar research name answers none of those questions by itself.
Read the finished-product description
The Forzinity prescribing information describes a particular sterile solution with specified ingredients, packaging, storage and clinical instructions. Those details belong to that medicine. They are not a preparation guide for a research powder.
A research vial cannot acquire the medicine's approved status by matching an ingredient name or nominal amount. Nor does a paper about the active substance authenticate a vendor's lot. These are different types of evidence, with different verification requirements.
Why the distinction changes an answer
A question about a prescribed Forzinity product belongs with its prescriber and dispensing pharmacist, using current product information. A question about an independently purchased research material first raises unresolved identity and suitability issues. The medical evidence cannot bridge those gaps automatically.
Similarly, a United States approval is a jurisdiction-specific decision. It is not proof of authorization in Canada or another market.
When reading an SS-31 article, look for a clear statement of the product and indication. If the article moves directly from a brand approval to an unrelated vial or a general wellness promise, an essential part of the argument is missing.